PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.

Abstract Prostate cancer patients treated with high dose rate brachytherapy and external beam radiation therapy were stratified by risk group for analysis to determine whether androgen deprivation therapy (ADT) affected outcome.
PMID
Related Publications

Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.

A systematic overview of radiation therapy effects in prostate cancer.

Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.

Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.

Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.

Authors

Mayor MeshTerms
Keywords
Journal Title american journal of clinical oncology
Publication Year Start




PMID- 19398902
OWN - NLM
STAT- MEDLINE
DA  - 20090807
DCOM- 20090902
LR  - 20101118
IS  - 1537-453X (Electronic)
IS  - 0277-3732 (Linking)
VI  - 32
IP  - 4
DP  - 2009 Aug
TI  - Excellent results from high dose rate brachytherapy and external beam for
      prostate cancer are not improved by androgen deprivation.
PG  - 342-7
LID - 10.1097/COC.0b013e31818cd277 [doi]
AB  - PURPOSE: Prostate cancer patients treated with high dose rate brachytherapy and
      external beam radiation therapy were stratified by risk group for analysis to
      determine whether androgen deprivation therapy (ADT) affected outcome. METHODS:
      From 1991 through 1998, 411 patients were treated with 4 fractions of 5.5 to 6.0 
      Gy high dose rate brachytherapy and a total of 36.0 to 39.6 Gy external beam
      radiation therapy (dose escalation over time). The dataset was prospective.
      Administration of ADT was not randomized, but it was the primary study variable. 
      During this period, ADT was administered across all risk groups for various
      indications. It did not necessarily reflect advanced disease or large prostate
      size. There were 200 patients in the "ADT Group" (20% low, 48% intermediate, and 
      32% high risk) and 211 in the "No ADT Group" (33% low, 44% intermediate, 23% high
      risk). The median follow-up was 6.4 years. Cases were grouped according to low,
      intermediate, and high risk groups to reduce the effects of unrecognized
      selection bias for or against the ADT group. The prostate specific antigen (PSA) 
      nadir plus 2.0 ng/ml (nadir + 2) was used as the biochemical control end point.
      Local control, PSA progression-free survival, distant metastasis free survival,
      and cause-specific survival were compared. RESULTS: The 10 year PSA-PFS (nadir + 
      2) for all 411 patients was 81%. The results stratified by risk group were: low
      92%, intermediate 87%, and high 63%. The low and intermediate risk groups were
      not statistically different from one another but they were both significantly
      better than the high risk group. ADT versus No ADT 10-year survival showed no
      significant differences for any outcome variable: PSA-PFS (83% vs. 81% ns), local
      control (97% vs. 99%), distant metastasis free survival (94% vs. 97%), and
      cause-specific survival (97% vs. 97%). A subset analysis of PSA-PFS (nadir + 2)
      stratified by risk group revealed no difference between the ADT and No ADT
      groups. CONCLUSIONS: high dose rate brachytherapy and external beam radiation
      therapy resulted in high rates of local control, PSA progression-free survival,
      distant metastasis free survival, and cause-specific survival in all risk groups.
      Improved outcome from the use of androgen deprivation was not observed.
FAU - Demanes, D Jeffrey
AU  - Demanes DJ
AD  - California Endocurietherapy Cancer Center, 3012 Summit Street Suite 2675,
      Oakland, CA 94610, USA. [email protected]
FAU - Brandt, David
AU  - Brandt D
FAU - Schour, Lionel
AU  - Schour L
FAU - Hill, Dennis R
AU  - Hill DR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Clin Oncol
JT  - American journal of clinical oncology
JID - 8207754
RN  - 0 (Androgen Antagonists)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Androgen Antagonists/*administration & dosage
MH  - Brachytherapy/*methods
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Dose-Response Relationship, Radiation
MH  - Drug Resistance
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Probability
MH  - Prospective Studies
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Neoplasms/*drug therapy/mortality/pathology/*radiotherapy
MH  - Radiotherapy Dosage
MH  - Reference Values
MH  - Risk Assessment
MH  - Statistics, Nonparametric
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2009/04/29 09:00
MHDA- 2009/09/03 06:00
CRDT- 2009/04/29 09:00
AID - 10.1097/COC.0b013e31818cd277 [doi]
PST - ppublish
SO  - Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277.